All In Biotech

Drug Trial Radar · NCT06280391

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 314 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

314

Actual

Start

Feb 20, 2024

Primary completion

Sep 16, 2025

Study completion Feb 2, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study was to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive). Study details include: * The study duration (screening, 24-52-week treatment, 20-week safety follow-up) was up to 47-77 weeks * The treatment duration was up to 24-52 weeks * The follow-up duration was 20 weeks * Site/phone visits were at a monthly interval

Conditions

  • Bronchiectasis

Interventions

  • Itepekimab (SAR440340)Drug

    * Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous

  • PlaceboDrug

    * Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Adjudicated Moderate or Severe Pulmonary Exacerbations (PEs) Over the Treatment PeriodTime frame: Baseline (Day 1) up to Week 24 to 52

Locations

117 sites in 20 countries. Site status is shown where the registry gives one.

  • Pulmonary Associates - Phoenix - East McDowell Road- Site Number : 8400012

    Phoenix, Arizona

  • Southern California Institute for Respiratory Diseases- Site Number : 8400002

    Los Angeles, California

  • Allianz Research Institute- Site Number : 8400013

    Westminster, California

  • Allianz Research Institute CO- Site Number : 8400038

    Aurora, Colorado

  • University of Connecticut Health Center- Site Number : 8400020

    Farmington, Connecticut

  • Yale New Haven Hospital- Site Number : 8400065

    New Haven, Connecticut

  • Advanced Pulmonary Research Institute- Site Number : 8400007

    Loxahatchee Groves, Florida

  • High Quality Research- Site Number : 8400047

    Miami, Florida

  • Avanza Medical Research Center- Site Number : 8400018

    Pensacola, Florida

  • Private Practice - Dr. Frank Hull - Plantation- Site Number : 8400010

    Plantation, Florida

  • Northwestern Memorial Hospital- Site Number : 8400043

    Chicago, Illinois

  • University of Kansas Medical Center- Site Number : 8400045

    Kansas City, Kansas

  • University of Michigan Health System - Ann Arbor- Site Number : 8400055

    Ann Arbor, Michigan

  • Pulmonary and Medicine Associates- Site Number : 8400057

    Warren, Michigan

  • Washington University- Site Number : 8400046

    St Louis, Missouri

  • NYU Langone Medical Center- Site Number : 8400032

    New York, New York

  • Southeastern Research Center- Site Number : 8400008

    Winston-Salem, North Carolina

  • Clinical Research Associates of Central PA - Dubois- Site Number : 8400005

    DuBois, Pennsylvania

  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400039

    Philadelphia, Pennsylvania

  • Medical University of South Carolina - Charleston - Jonathan Lucas Street- Site Number : 8400027

    Charleston, South Carolina

  • Metroplex Pulmonary and Sleep Center- Site Number : 8400014

    McKinney, Texas

  • Pioneer Research Solutions, Inc.- Site Number : 8400048

    Sugar Land, Texas

  • The University of Texas Health Center at Tyler- Site Number : 8400053

    Tyler, Texas

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0320008

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320007

    Córdoba, Argentina

  • Investigational Site Number : 0320006

    Mendoza, Argentina

  • Investigational Site Number : 0320005

    San Miguel de Tucumán, Argentina

  • Incor - Instituto do Coracao- Site Number : 0760002

    São Paulo, Brazil

  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001

    Porto Alegre, Rio Grande do Sul, Brazil

  • WM Pesquisas Clínicas em Doenças Respiratórias- Site Number : 0760004

    Porto Alegre, Rio Grande do Sul, Brazil

  • Investigational Site Number : 1240003

    Guelph, Ontario, Canada

  • Investigational Site Number : 1240005

    Sherbrooke, Quebec, Canada

  • Investigational Site Number : 1240001

    Trois-Rivières, Quebec, Canada

  • Investigational Site Number : 1520001

    Talca, Maule Region, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520004

    Quillota, Valparaiso, Chile

  • Investigational Site Number : 1560005

    Beijing, China

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.